COA 2020: First-time Diagnosis of Osteosarcoma in a Dinosaur

Ifosfamide-based chemotherapy yields high survival rate for treatment of osteosarcoma

Drug Des Devel Ther. 2015 Nov 4;9:5925-32

Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy

Cancer. 2012 Dec 1;118(23):5888-93

MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients

Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566

Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival

J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095

Osteosarcoma: methotrexate & doxorubicin versus methotrexate, etoposide & ifosfamide

Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30

Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma

J Clin Oncol. 2012 Jun 10;30(17):2112-8. doi: 10.1200/JCO.2011.38.4420. Epub 2012 May 7

Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma

Adv Clin Exp Med. 2022 01-Mar;():. 10.17219/acem/142332

COA 2022: Surgical Resection Type and Adjuvant Therapies on Survival of Primary Spine Sarcomas